{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:31:00Z","timestamp":1791556260202,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK","award":["LS3215"],"award-info":[{"award-number":["LS3215"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disease associated with vascular inflammation and multisystem organ damage. The literature reporting EGPA incidence or prevalence is limited. We performed a systematic literature review and meta-analysis to describe the incidence, prevalence, and disease burden associated with EGPA. Real-world, observational, English-language studies in MEDLINE, MEDLINE In-Process, and Embase up to 6 June, 2019, were included. A single investigator screened all identified titles\/abstracts and extracted data; an additional, independent investigator repeated the screening and validated the extracted data. A random-effects meta-analysis was conducted to generate pooled estimates for EGPA incidence and prevalence. Data from 100 eligible publications were extracted (32 with incidence\/prevalence data, 65 with morbidity\/healthcare resource data; 3 with both types of data). Significant evidence of between-study heterogeneity for reported incidence (p\u2009=\u20090.0013\u20130.0016) and prevalence (p\u2009=\u20090.0001\u20130.0006) estimates was observed. Global and European pooled estimates (95% confidence interval) of EGPA incidence were 1.22 (0.93, 1.60) and 1.07 (0.94, 1.35) cases per million person-years, respectively; global and European pooled estimates (95% confidence interval) for EGPA prevalence were 15.27 (11.89, 19.61) and 12.13 (6.98, 21.06) cases per million individuals, respectively. The proportions of patients experiencing relapses, or who had nasal polyps or severe asthma, varied considerably across studies. EGPA healthcare resource use was high, with inpatient admissions and emergency department visits reported for 17\u201342% and 25\u201342% of patients, respectively. Our results indicate that although global and European EGPA incidence and prevalence is low, the associated disease burden is substantial.\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"3\"\/>\n                        <jats:td><jats:bold>Key points<\/jats:bold>\u2022 <jats:italic>We performed a systematic literature review and meta-analysis of real-world, observational studies describing the incidence, prevalence, and disease burden associated with eosinophilic granulomatosis with polyangiitis (EGPA).<\/jats:italic>\u2022 <jats:italic>Based on meta-analysis data from 35 eligible studies reporting incidence and prevalence, the incidence and prevalence of EGPA were low (globally 1.22 cases per million person-years and 15.27 cases per million individuals, respectively).<\/jats:italic>\u2022 <jats:italic>Among the 49 studies with morbidity and\/or healthcare resource data, most reported a large proportion of patients with EGPA relapses and comorbidities of nasal polyps and severe asthma.<\/jats:italic>\u2022 <jats:italic>Healthcare resource use was also high among patients with EGPA in these studies, with inpatient admissions and emergency department visits reported for 17\u201342% and 25\u201342% of patients, respectively. Taken together, these data indicate the substantial disease burden associated with EGPA.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-021-05783-8","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T23:05:43Z","timestamp":1624403143000},"page":"4829-4836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Rupert W.","family":"Jakes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namhee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Nordstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Goulding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Fahrbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Tarpey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Van Dyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"5783_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11926-018-0736-2","volume":"20","author":"EP Navarro-Mendoza","year":"2018","unstructured":"Navarro-Mendoza EP, Tob\u00f3n GJ (2018) Eosinophilic granulomatosis with polyangiitis: newer therapies. Curr Rheumatol Rep 20:23","journal-title":"Curr Rheumatol Rep"},{"key":"5783_CR2","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D et al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376:1921\u20131932","journal-title":"N Engl J Med"},{"key":"5783_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond C, Pagnoux C, Khellaf M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270\u2013281","journal-title":"Arthritis Rheum"},{"key":"5783_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.08570814","volume":"11","author":"AC Wiseman","year":"2016","unstructured":"Wiseman AC (2016) Immunosuppressive medications. Clin J Am Soc Nephrol 11:332\u2013343","journal-title":"Clin J Am Soc Nephrol"},{"key":"5783_CR5","unstructured":"Yasir M, Goyal A, Bansal P, Sonthalia S. Treasure Island (FL): StatPearls Publishing; 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK531462\/. Accessed 30 July 2020"},{"key":"5783_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","volume":"63","author":"JG Lanham","year":"1984","unstructured":"Lanham JG, Elkon KB, Pusey CD, Hughes gR, (1984) Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine 63:65\u201381","journal-title":"Medicine"},{"key":"5783_CR7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094\u20131100","journal-title":"Arthritis Rheum"},{"key":"5783_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Arthritis Rheum 37:187\u2013192","journal-title":"Arthritis Rheum"},{"key":"5783_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk R, Bacon P et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.37715","journal-title":"Arthritis Rheumatol"},{"key":"5783_CR10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222\u2013227","journal-title":"Ann Rheum Dis"},{"key":"5783_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336\u2013341","journal-title":"Int J Surg"},{"key":"5783_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","volume":"3","author":"Z Munn","year":"2014","unstructured":"Munn Z, Moola S, Riitano D, Lisy K (2014) The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Health Policy Manag 3:123","journal-title":"Int J Health Policy Manag"},{"key":"5783_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001198","author":"M Gokhale","year":"2019","unstructured":"Gokhale M, Bell CF, Doyle S, Fairburn-Beech J, Steinfeld J, Van Dyke MK (2019) Prevalence of eosinophilic granulomatosis with polyangiitis and associated health care utilization among patients with concomitant asthma in US commercial claims database. J Clin Rheumatol. https:\/\/doi.org\/10.1097\/RHU.0000000000001198","journal-title":"J Clin Rheumatol"},{"key":"5783_CR14","doi-asserted-by":"crossref","unstructured":"Bell C, Shen Q, Sloane J, Katz A (2018) Bell C, Lau M, Shen Q. Clinical and economic characteristics of patients diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United States. American Thoracic Society. In C41: HEALTH SERVICES RESEARCH IN PULMONARY DISEASE:A4951-A4951","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A5984"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05783-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05783-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T01:03:32Z","timestamp":1637197412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05783-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5783"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05783-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RWJ, NK, and MVD are employees of GSK and hold stocks\/shares. BN, RG, KF, and JT are employees of Evidera, who received funding from GSK for this analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}